Novavax vaccine protects 100% against moderate to severe COVID-19 in large trial

Listen

Novavax said June 14 its vaccine is 100 percent effective at protecting against moderate to severe COVID-19 and 90.4 percent effective overall.

The data came from a phase 3 trial that enrolled 29,960 participants across 119 sites in the U.S. and Mexico. Novavax said it recruited participants from the communities and demographic groups most affected by COVID-19.

Should the vaccine be cleared by the FDA, Novavax is ready to manufacture 150 million doses each month by the end of 2021.

 

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Whitepapers

Featured Webinars